» Articles » PMID: 20066739

Rupintrivir is a Promising Candidate for Treating Severe Cases of Enterovirus-71 Infection

Overview
Specialty Gastroenterology
Date 2010 Jan 13
PMID 20066739
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To evaluate the suitability of rupintrivir against Enterovirus 71 (EV71) induced severe clinical symptoms using computational methods.

Methods: The structure of EV71 3C protease was predicted by homology modeling. The binding free energies between rupintrivir and EV71 3C and human rhinovirus 3C protease were computed by molecular dynamics and molecular mechanics Poisson-Boltzmann/surface area and molecular mechanics generalized-born/surface area methods. EV71 3C fragments obtained from clinical samples collected during May to July 2008 in Shanghai were amplified by reverse-transcription and polymerase chain reaction and sequenced.

Results: We observed that rupintrivir had favorable binding affinity with EV71 3C protease (-10.76 kcal/mol). The variability of the 3C protein sequence in isolates of various outbreaks, including those obtained in our hospital from May to July 2008, were also analyzed to validate the conservation of the drug binding pocket.

Conclusion: Rupintrivir, whose safety profiles had been proved, is an attractive candidate and can be quickly utilized for treating severe EV71 infection.

Citing Articles

Update on enteroviral protease 2A: Structure, function, and host factor interaction.

Liu Y, Li J, Zhang Y Biosaf Health. 2025; 5(6):331-338.

PMID: 40078741 PMC: 11894969. DOI: 10.1016/j.bsheal.2023.09.001.


Emerging Therapeutics in the Fight Against EV-D68: A Review of Current Strategies.

Kalam N, Balasubramaniam V Influenza Other Respir Viruses. 2024; 18(12):e70064.

PMID: 39702696 PMC: 11659119. DOI: 10.1111/irv.70064.


In vitro synergistic antiviral activity of repurposed drugs against enterovirus 71.

Jitobaom K, Boonarkart C, Thongon S, Sirihongthong T, Sornwong A, Auewarakul P Arch Virol. 2024; 169(8):169.

PMID: 39078431 DOI: 10.1007/s00705-024-06097-1.


Novel Anti-Enterovirus A71 Compounds Discovered by Repositioning Antivirals from the Open-Source MMV Pandemic Response Box.

Lochaiyakun N, Srimanote P, Khantisitthiporn O, Thanongsaksrikul J Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931452 PMC: 11206571. DOI: 10.3390/ph17060785.


Research progress on pathogenic and therapeutic mechanisms of Enterovirus A71.

Lai J, Li Z, Pan L, Huang Y, Zhou Z, Ma C Arch Virol. 2023; 168(10):260.

PMID: 37773227 DOI: 10.1007/s00705-023-05882-8.


References
1.
Lall M, Jain R, Vederas J . Inhibitors of 3C cysteine proteinases from Picornaviridae. Curr Top Med Chem. 2004; 4(12):1239-53. DOI: 10.2174/1568026043387836. View

2.
Humphrey W, Dalke A, Schulten K . VMD: visual molecular dynamics. J Mol Graph. 1996; 14(1):33-8, 27-8. DOI: 10.1016/0263-7855(96)00018-5. View

3.
Xiang W, Harris K, Alexander L, Wimmer E . Interaction between the 5'-terminal cloverleaf and 3AB/3CDpro of poliovirus is essential for RNA replication. J Virol. 1995; 69(6):3658-67. PMC: 189081. DOI: 10.1128/JVI.69.6.3658-3667.1995. View

4.
Ho M, CHEN E, Hsu K, Twu S, Chen K, Tsai S . An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999; 341(13):929-35. DOI: 10.1056/NEJM199909233411301. View

5.
Luthy R, Bowie J, Eisenberg D . Assessment of protein models with three-dimensional profiles. Nature. 1992; 356(6364):83-5. DOI: 10.1038/356083a0. View